Summary :
CDMO giant Catalent completed expansion projects worth $10 million that added large-scale isolator units to its Malvern, Pennsylvania, and Dartford, U.K., manufacturing facilities.
With the new units, Catalent can provide clinical and commercial scale jet milling to be conducted under enhanced containment conditions, the company said. Micronizers, which are part of the new systems, will provide a greater degree of safety by eliminating the risk of dust explosion for compounds with low minimum ignition points.
Catalent
Other features of the upgrades include continuous milling operations, clean-in-place automated washing systems and improved flexible sampling schemes that don’t need external equipment.
“Micronization is a well-established technology to help improve the solubility of oral drugs, and there continues to be a growing need for safe manufacturing and containment technologies required for the development of highly potent APIs,” James Walter, a Catalent vice president, said in a statement. “These expansions provide the increased capacity needed to meet current and future demand for high potent, high value micronization.”
Catalent, like other large CDMOs, has flourished during the COVID-19 pandemic because of explosive growth fueled by the production of therapies to fight the virus. Catalent reported revenues of $4 billion in its fiscal year 2021, a 26% increase at constant currencies versus the previous year. The company has forecast revenue growth between 8% and 13% for 2022.
Catalent
Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians.Catalent is an exciting and growing international company where our professionals work directly with pharma, biopharma and consumer health companies of all sizes to advance new medicines from early development to clinical trials and to the market, for the benefit of patients around the world.
Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc. Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. … Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians.
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/ (Pharmaceutical Databases)